Navigation Links
Scientists find new targets that could increase effectiveness of breast cancer treatments
Date:6/5/2014

JUPITER, FL, June 5, 2014 Scientists from the Florida campus of The Scripps Research Institute (TSRI) have found new targets for potential intervention in breast cancer. These new targets could eventually increase effectiveness and reduce the undesirable side effects associated with current treatments.

The study was published online ahead of print on June 5, 2014 by the journal Structure.

Approximately two out of three breast cancers are driven by receptors that bind the hormones estrogen and progesteronewhen the hormones bind to these receptors in cancer cells, they signal the cancer cells to grow. What makes the progesterone receptor therapeutically interesting is that it has two activation domainsAF1 and AF2. Normally, both are needed for full activation of the receptor.

"Using hydrogen-deuterium exchange technology, our study pinpoints just how AF2 communicates with AF1the first evidence of the long-range interaction between these two functional domains," said Patrick R. Griffin, a TSRI professor who led the study. "These findings support further research to look for promising small molecules that block that interaction."

The findings are especially important because in some mutations AF2 is deleted, yet the receptor still drives the cancer using its AF1 domain. Current drugs used for treating these cancers only target the AF2 domain, so with nothing to bind to, they do not work at all. While several studies have shown the importance of AF1, its binding domain is remarkably dynamic, frequently shifting shape and making it difficult to target with drugs.

In the new study, the scientists used an advanced technology known as hydrogen-deuterium exchange mass spectrometry (HDX) to measure the intricate interactions between the AF1 and AF2 domains of the progesterone receptor.

HDX mass spectrometry is a high-precision, high-sensitivity mapping technique that enabled the scientists to determine the specific regions of the receptor that are altered upon interaction. This information was used to infer structural changes that result from the interaction and to probe the conformational flexibility of intact multidomain proteins.

In addition to exploring potential new drugs for breast cancer, the researchers also hope to investigate the implications for prostate cancer, another hormone-driven disease.

"Many features of the androgen receptor are similar to progesterone receptor, as they belong to the same subfamily of steroid receptors," said Devrishi Goswami, the first author of the study and a member of the Griffin laboratory. "It could work the very same way. So these new insights may also help in finding new approaches to treating hormone-therapy-resistant prostate cancer."


'/>"/>

Contact: Eric Sauter
esauter@scripps.edu
267-337-3859
Scripps Research Institute
Source:Eurekalert  

Related biology news :

1. Scientists discover the basis of allergic reactions
2. MU scientists successfully transplant, grow stem cells in pigs
3. Scientists capture most detailed images yet of humans tiny cellular machines
4. NUS scientists demonstrate rare chemical phenomenon to harvest solar energy
5. Glow-in-the-dark tool lets scientists find diseased bats
6. Listening helps scientists track bats without exposing the animals to disease
7. Scientists control rapid re-wiring of brain circuits using patterned visual stimulation
8. Vines choke a forests ability to capture carbon, Smithsonian scientists report
9. Imaging scientists develop a better tool for tracking MS
10. Scientists map the worst times of day for people allergic to grass pollen
11. Scientists discover potential new target for cancer immunotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scientists find new targets that could increase effectiveness of breast cancer treatments
(Date:1/12/2017)... and PUNE, India , January 12, 2017 ... Forecasts, 2015 - 2022," projects that the global biometric technology market is expected to ... 2016 to 2022. Continue Reading ... ...      ...
(Date:1/6/2017)... 5, 2017  Delta ID Inc., a leader in ... for automotive at CES® 2017. Delta ID has collaborated ... demonstrate the use of iris scanning as a secure, ... driver in a car, and as a way to ... Delta ID and Gentex will demonstrate (booth ...
(Date:12/22/2016)... December 22, 2016 SuperCom (NASDAQ: ... solutions for the e-Government, Public Safety, HealthCare, and Finance sectors announced ... has been selected to implement and deploy a community-based supportive services ... Northern California , further expanding its presence in the state. ... This new program, ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... ... January 18, 2017 , ... LabRoots , the leading ... the world, was today awarded the "Best Science & Technology Social Networking Service ... and decided upon by a dedicated team of researchers and analysts. , The ...
(Date:1/19/2017)... ... January 19, 2017 , ... DaVita Clinical Research ... drug and device development, and Prism Clinical Research , a leader in ... Verified Clinical Trials (VCT) has been selected by both companies as ...
(Date:1/19/2017)... -- Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a U.S. ... and inoperable solid tumor cancers, announced today that Dr. ... Bio, will present at the Phacilitate Immunotherapy World Conference ... Hotel in Miami, Florida . ... Therapeutic Approaches – Expanding the Reach of Cancer Immunotherapy ...
(Date:1/19/2017)... , Jan. 18, 2017 BD (Becton, Dickinson and ... announced today that it will host a live webcast of its ... p.m. (ET). The webcast can be accessed from ... for replay through Tuesday, January 31, 2017. ... About BD BD is a ...
Breaking Biology Technology: